

NON-ICU COVID19 CARE PATHWAY

Quick Reference Guide

Supplemental to COVID19 PowerPlan Utilization

Hospital Medicine

Revision as of 07.15.20

Indicate level of suspicion of COVID							
In your assessment and plan based on History, Physical and Diagnostic testing as below							
+ CT scan suggestive of COVID or CXR with bilateral infiltrates	Any of the following lab abnormalities: <ul style="list-style-type: none"> • Lymphopenia (35-75% of the cases) 						
Hx of community/ family contact with COVID or travel to high risk areas	<ul style="list-style-type: none"> • Increased values of CRP or ESR (75–93% of cases) • LDH elevation (27–92% of cases) 						
Fever 101 or greater: 75% of patients	<ul style="list-style-type: none"> • Elevated D-dimer 						
Influenza and RSV-PCR negative turnaround time 1 hour if available	<ul style="list-style-type: none"> • Low procalcitonin 						
Isolation Tips							
Special droplet (N95 + eye protection) + Contact (gown + gloves). Note: for COVID19 + COVID PUI and any patient on aerosol generating procedures regardless of isolation status	If COVID-19 testing is negative , consider the following: <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="background-color: #e0e0e0;">High Probability</td> <td>Keep on unit and re-test</td> </tr> <tr> <td style="background-color: #e0e0e0;">Moderate Probability</td> <td>Re-evaluate for possible repeat testing and/or continued observation</td> </tr> <tr> <td style="background-color: #e0e0e0;">Low Probability</td> <td>Please transfer off Cohort and notify PCP* (T/C Home)</td> </tr> </table>	High Probability	Keep on unit and re-test	Moderate Probability	Re-evaluate for possible repeat testing and/or continued observation	Low Probability	Please transfer off Cohort and notify PCP* (T/C Home)
High Probability		Keep on unit and re-test					
Moderate Probability		Re-evaluate for possible repeat testing and/or continued observation					
Low Probability		Please transfer off Cohort and notify PCP* (T/C Home)					
Aerosolizing procedures in negative pressure room if available							
Avoid unnecessary aerosolizing procedures e.g. nebulization (switch to inhalers), non-invasive ventilation (CPAP, BiPAP)							
To help reduce risk for potential exposure due to false negatives							
<ul style="list-style-type: none"> • High risk patients from cohort units with <i>1 negative COVID 19 PCR</i> <ul style="list-style-type: none"> ○ Should remain on Cohort unit until 2nd test results are available ○ Remain on special contact/droplet precautions • Patients with 1 negative PCR and no 2nd test results pending <ul style="list-style-type: none"> ○ Must remain on droplet precautions for the remainder of their stay. • Patients with 2 negative PCRs and meeting CDC criteria for discontinuing precautions <ul style="list-style-type: none"> ○ May have precautions discontinued 							
Therapeutic options should be based on severity using the following scale:							
<ul style="list-style-type: none"> • 0 = Patient on room air • 1 = Patient requires supplemental O2 via NC up to a max of 6L • 2 = Patient requires supplemental O2 in addition to ONE of the following <ul style="list-style-type: none"> ○ Dyspnea or staccato speech at rest or after minimal activity ○ RR > 22 on 6L ○ PaO2 <65 mmHg with 6L ○ Worsening infiltrates on imaging (CT preferred) 	<ul style="list-style-type: none"> • 3 = Patient requires HFNC, CPAP or NIV • 4 = Patient intubated with minimal support PaO2/FiO2 or using PS • 5 = Patient intubated with PaO2/FiO2 > 150 mmHg • 6 = Patient intubated with PaO2/FiO2 < 150 mmHg • 7 = Patient intubated with PaO2/FiO2 < 150 mmHg AND requiring vasopressor support • 8 = Patient intubated in prone position or ECMO 						
Severity Score	Treatment for Hospitalized Patients*						
0	Support care only – if clinically stable, consider discharge for self-quarantine						
1	Remdesivir (based on criteria and availability) Dexamethasone 6mg po or IV daily** for up to 10 days						
2	Remdesivir (based on criteria and availability) Corticosteroids Consider Convalescent Plasma (call Research Pharmacist: 413-519-7056)						
3	Corticosteroids Tocilizumab (ICU/ID consult) Consider Convalescent Plasma (call Research Pharmacist: 413-519-7056)						
≥4	Corticosteroids Tocilizumab (ICU/ID consult) Consider Convalescent Plasma (call Research Pharmacist: 413-519-7056)						

*Patient can be discharged whenever clinically indicated. Full duration of therapy does not need to be completed if patient is suitable for discharge to home. Isolation should be maintained at home for the time period recommended.

**Full results pending publication

Upon admission to Cohort Unit, please notify PCP^ of patient's admission

*****Consults:** Please limit to only those deemed necessary based upon clinical picture

^PCP: original group pt would have been assigned to without Cohort unit

https://www.covidprotocols.org/pdf/QuickGuide_Hospitalist.pdf

NON-ICU COVID19 CARE PATHWAY

Quick Reference Guide

Supplemental to COVID19 PowerPlan Utilization

Hospital Medicine

Revision as of 07.15.20

Lab Work: STAT order COVID-19 PCR & HIV 1/2 Antigen/Antibody Screen Fourth Generation	
Upon Admission	CBC, BMP, Magnesium, CRP, LFT, CPK, LDH, PTT, INR, procalcitonin, troponin, NT-proBNP, D-dimer, ferritin
Daily	CBC, BMP, Magnesium <i>(If patient is in ICU: add troponin, CPK)</i>
Every Other Day	LFT, CPK, troponin, CRP, LDH, D-dimer, ferritin <i>(If patient on propofol: add triglyceride)</i>
If Clinically Worse	LFT, CPK, troponin, CRP, procalcitonin, LDH, ferritin, D-dimer, fibrinogen, PTT, INR

Lab results to expect: *Potential marker of disease severity	
Normal WBC	Elevated AST*/ALT
Lymphopenia*	Elevated CRP*
Mild thrombocytopenia	Elevated LDH*
BMP with elevated Cr	Elevated D-dimer*
Normal procalcitonin	Elevated troponin

Care Recommendations	
CT Chest	NOT necessary for diagnosis (caution w CT d/t increase risk of spread thru transport, break in isolation and risk of AKI)
Daily CXR	NOT necessary unless it will change management plan
IV Fluids	Conservative fluid management is important to mitigate risk of progression of respiratory failure
Steroids	Avoid using empirically, only use if other indication (i.e. Pt. requires supplemental O2) (Refer to PP)
Antibiotics	Utilize if bacterial superinfection likely (Review with pharmacy and/or consult ID)
Code Blue	Don PPE prior to entering room, even if this delays CPR. Stop chest compressions for intubation to decrease secretions

Non-ICU COVID-19 Care Checklist	
Oxygenation	<input type="checkbox"/> If requiring oxygen, attempt to wean O2 at least once per shift and document if desats <input type="checkbox"/> If on RA at rest, ambulate the patient on RA at least once per shift and document if desats <input type="checkbox"/> If O2 requirements increase by >1L, consider putting the patient in prone position (if tolerates) (Refer to Prone PP) <input type="checkbox"/> Consider utilization of heated high flow O2 <i>(Unless patient condition warrants, heated high flow O2 should stay on PCU)</i>
Positioning	<input type="checkbox"/> Encourage prone position (as much as tolerated) if requiring >2L via NC <input type="checkbox"/> If patient cannot tolerate prone position, encourage lying on the side or sitting upright
Medications	<input type="checkbox"/> Review for: <ul style="list-style-type: none"> o If requiring oxygen: <ul style="list-style-type: none"> ▪ Dexamethasone...Severity Score 1 & Above <i>(Consider Escalating Doses as Severity Score Increased)</i> ▪ Remdesivir (contraindicated in renal failure, liver enzymes 5x nl)...Severity Score 1-2 Recommended o IL-6 antagonist (use with very specific requirements and ID Consult)...Severity Score 3 and Above <input type="checkbox"/> Antibiotics for bacterial superinfection, discontinue if not identified <input type="checkbox"/> VTE prophylaxis <ul style="list-style-type: none"> o Preferably Lovenox or heparin o If SCD only and patient is refusing, notify physician to consider pharmacoprohylaxis o If D-dimer is trending up or very elevated, consider therapeutic anticoagulation doses
Labs	<input type="checkbox"/> Generally check at least every 2-3 days (more often if patient status is changing) <ul style="list-style-type: none"> o D-dimer, Ferritin, CRP, CBC, CMP <input type="checkbox"/> May recheck for negative COVID 7 days after last positive test / onset of symptoms
Hydration	<input type="checkbox"/> Avoid excessive hydration/volume overload; discontinue continuous fluids if patient is taking PO well
Nutrition	<input type="checkbox"/> Document % meal consumed <input type="checkbox"/> If routinely <50% consumed, request order for dietary supplement
Patient Activity	<input type="checkbox"/> If requiring >3L O2, minimize activity without oxygen (as these patients desaturate quickly) <ul style="list-style-type: none"> o Have bedside commode/bed pan/diaper <input type="checkbox"/> Encourage frequent Incentive Spirometer use/have at bedside
Criteria rapid response/ obtain ABG/ consider upgrade to ICU:	<input type="checkbox"/> Requiring >6L NC <input type="checkbox"/> Low PaO2 on ABG while on 6L or more via NC <input type="checkbox"/> Increased respiratory rate/work of breathing <input type="checkbox"/> Altered mental status

Remdesivir Process	
Medical Provider has patient meeting FDA EUA criteria	
Medical Provider Flagler/Lake/Polk/Volusia: Order thru Multi-State COVID PowerPlan by selecting "Consult to pharmacy-remdesivir" Orange/Osceola/Seminole: Order thru Remdesivir PowerPlan in PowerChart . Enter Consult to Pharmacy for Remdesivir.	
Pharmacist profiles order once delivered by state DOH	

^APCP: original group pt would have been assigned to without Cohort unit
https://www.covidprotocols.org/pdf/QuickGuide_Hospitalist.pdf

NON-ICU COVID19 CARE PATHWAY

Quick Reference Guide

Supplemental to COVID19 PowerPlan Utilization

Hospital Medicine

Revision as of 07.15.20

COVID-19 Discharge Criteria Recommendation

Discharge criteria from the ED:	Discharge criteria from IP:
<ul style="list-style-type: none"> • Ambulatory O2 sat >92% on RA or ≤2L O2 • RR <20 • Tolerating PO • Baseline mental status • Able to quarantine <ul style="list-style-type: none"> ○ CM to address: <ul style="list-style-type: none"> • Home O2 (if indicated) • Home monitoring program (Vivify) <ul style="list-style-type: none"> ○ Pulse Ox ○ Thermometer ○ Virtual visit ○ Education • Disposition for special populations 	<ul style="list-style-type: none"> • Ambulatory O2 sat >92% on RA or ≤2L <ul style="list-style-type: none"> ○ For patients requiring up to 4L O2, stable without escalating oxygen needs ≥48 hours • Inflammatory markers stable or trending down (i.e., LDH, ferritin, CRP, D-dimer) • If repeat CxR performed, no worsening of infiltrates • Tolerating PO • Baseline mental status • Able to quarantine <ul style="list-style-type: none"> ○ CM to address: <ul style="list-style-type: none"> • Home O2 (if indicated) • Home monitoring program (Vivify) <ul style="list-style-type: none"> ○ Pulse Ox, Thermometer ○ Virtual visits ○ Education • Disposition for special populations

Capacity Mgt/Reverse Triage Process
<ul style="list-style-type: none"> • Home Monitoring Program for COVID-19 + or PUIs 18y/o or older (pending results) to be discharged and monitored daily by a centralized nurse monitoring team <ul style="list-style-type: none"> ○ All patients discharging with RPM will have a Home Physician Group referral ○ Patients needing to be more closely monitored may have HHC and/or DME (Oxygen) ordered along with the home monitoring/Home Physicians Group (HPG) visit. • Inpatient Discharge Triage Tool (IDTT) <ul style="list-style-type: none"> ○ Daily assessment of discharge readiness for all non-ICU patients

Discharge Medications:
<ul style="list-style-type: none"> • Dexamethasone 6mg PO qday x5 days (if requiring oxygen during hospital stay or at discharge) <ul style="list-style-type: none"> ○ Recommend <u>against</u> glucocorticoids if not hypoxic and requiring supplemental oxygen • Cough suppressant +/- Albuterol HFA prn • Consider oral antibiotics if bacterial superinfection likely • Anticoagulation <ul style="list-style-type: none"> ○ High Risk: D-Dimer ≥3 <ul style="list-style-type: none"> • Consider CTA • Anticoagulation Algorithm ○ Moderate Risk: D-Dimer 1.5- <3 <ul style="list-style-type: none"> • Consider ASA ○ Low Risk: D-Dimer <1 <ul style="list-style-type: none"> • No Medications Recommended
<p>Link to treatment algorithm and anticoagulation pathway https://www.adventhealth.com/adventhealthtreatmentalgorithm</p>

Special Population
<ul style="list-style-type: none"> • SNF/ALF/Group Homes/Psych/Baker Act <ul style="list-style-type: none"> ○ Disposition to COVID-receiving facility, and two negative tests (24 hours apart) ○ *Recommend if test returns positive to repeat ≥48 hours later • Homeless/Shared living quarters <ul style="list-style-type: none"> ○ Hospital/state/city provided hotel room ○ Refer to COVID Homelessness Process with CM

Telehealth on Cohort Units

- Inpatient telehealth patient care on COVID units
- Please follow Tele visit guidelines
- <https://ahsonline.sharepoint.com/sites/TeleHealthResources>

Treatment Algorithm Link – One-stop shop for all SRC approved treatments at AdventHealth

<https://www.adventhealth.com/adventhealthtreatmentalgorithm>

[^]PCP: original group pt would have been assigned to without Cohort unit
https://www.covidprotocols.org/pdf/QuickGuide_Hospitalist.pdf